KLOW Stack
KLOW peptide blend · GHK-Cu BPC-157 TB-500 KPV stack · regenerative anti-inflammatory stack · klow peptide
Vendor GLOW mix plus KPV. Common advertised SKU is 80 mg at 50/10/10/10. Still a catalog pairing. Not an IBD drug, not a leaky-gut reset, not a synergy RCT.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Injury & tissue3/10
Adds KPV (α-MSH fragment) to a GLOW-style mix. Still a catalog pairing.
- Skin / cosmetic3/10
GHK-Cu is still ~62.5% of a 50/10/10/10 cake. Topical copper-peptide papers do not become a four-way NDA.
Compound card
- Class
- Vendor blend (GLOW components + KPV)
- Formula
- GHK-Cu + KPV + BPC-157 + TB-500 7-mer (vendor mix)
- Status
- Not FDA-approved · research use
How it works
KLOW is the GLOW cake plus KPV. Four lyophilized research SKUs: GHK-Cu, BPC-157, TB-500 as sold (usually Ac-LKKTETQ), and KPV (α-MSH residues 11–13, Lys-Pro-Val). The common advertised split is 80 mg at 50/10/10/10, so GHK-Cu is still 62.5% of every draw.
KPV’s literature is mouse colitis and NF-κB work (Dalmasso 2008, Kannengiesser 2008). That is not Crohn’s, not UC, not mast-cell activation syndrome, and not a reason this bottle is an “anti-inflammatory stack.” Adding a fourth powder does not create synergy. There is no published trial of the four together.
TB-500 identity stays the 7-mer problem. BPC-157 stays Category 2 and WADA S0. GHK-Cu stays copper and PIP. Read the four leaves. Then read the COA.
Source: PMID: 18492131 (GHK-Cu), PMID: 29936067 (BPC-157), PMID: 23084823 (TB-500 7-mer), PMID: 18061177 (KPV mouse colitis)
KPV does not make this an IBD drug. BPC-157 is still S0.
Four-peptide convenience is not a gastroenterology protocol. Mouse colitis papers on KPV stay on the KPV leaf. Titration tables you see elsewhere are milligram arithmetic of a 50/10/10/10 cake, not a studied schedule.
No published trial has tested GHK-Cu + KPV + BPC-157 + TB-500 together. Dalmasso 2008 and Kannengiesser 2008 are mouse colitis papers on KPV, not Crohn’s or UC approvals, and not a reason this bottle is “for inflammation.” TB-500 as sold is still usually the 7-mer.
What is in the vial
KLOW is GLOW with a fourth lyophilized powder in the cake: KPV (α-MSH 11–13). The common advertised SKU is 80 mg at 50/10/10/10. GHK-Cu is still ~62.5% of every draw. Adding KPV does not create a gut, mast-cell, or autoimmune indication.
GHK-Cu
50 mg in the advertised SKU62.5% of a 50/10/10/10 vial. Every titration step scales GHK-Cu faster than the other three.
Same copper tripeptide as GLOW. Still the majority of the cake. Still the usual PIP source.
KPV
10 mg in the advertised SKULys-Pro-Val. This is the only structural difference from GLOW. Difference ≠ superiority trial.
α-MSH C-terminal tripeptide. Murine NF-κB / colitis models. Not a human IBD drug.
BPC-157
10 mg in the advertised SKUDoes not become a gut protocol because KPV is in the same powder.
Same 15-mer as GLOW. Category 2. WADA S0.
TB-500
10 mg in the advertised SKUDaily micrograms in a GHK-Cu-heavy cake are not Tβ4 loading from a cardiac paper.
Same 7-mer identity problem as GLOW.
Pre-blend math
Common advertised cake: 50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500. Example reconstitution 3 mL bacteriostatic water → 26.7 mg/mL total blend. “KLOW 80 mg” is a vendor convention, not a monograph. If your vial is 20 mg or a different split, this table is wrong for your bottle. Use the blend calculator.
Concentration = 80 mg ÷ 3 mL. One U-100 unit = 0.01 mL ≈ 267 mcg total. Units = mL × 100.
Draw math for this advertised ratio
Arithmetic, not a dose recommendation15 units (0.15 mL) on a U-100 syringe is 0.15 mL. At 267 mcg/unit from a 80 mg / 3 mL cake, that is ~4.00 mg total blend. About 20 full draws before the vial is empty, ignoring priming waste.
How that draw compares to standalone folklore
Titration tables on other sites are arithmetic of this ratio, dressed as a protocol. We show the arithmetic. We do not promote the titration.
| Component | This draw | Standalone folklore | Read |
|---|---|---|---|
| GHK-Cu | ~2.5 mg / 15 U | 1–2 mg daily is a common standalone range | At 15–22.5 units this cake overshoots that folklore band because GHK-Cu is 62.5% of the vial |
| KPV | ~500 mcg / 15 U | Community logs often cite 200–500 mcg | Inside that folklore band at 15 units; still mouse-model evidence |
| BPC-157 | ~500 mcg / 15 U | 250–500 mcg daily | Inside that folklore band at 15 units |
| TB-500 | ~500 mcg / 15 U daily | 2–5 mg, 2×/week in many injury logs | Still a convenience microdose vs loading folklore |
Separate vials
If the job is “I want KPV,” buy KPV. Parking it inside a GHK-Cu-majority cake so you can say KLOW is not dose control. Separate syringes for separate vials.
| Peptide | Community range | Typical folklore frequency | Example recon math |
|---|---|---|---|
| GHK-Cu | 1–2 mg | Daily in community logs | 50 mg + 5 mL BAC → 10 mg/mL. 1 mg = 10 units. |
| KPV | 200–500 mcg | Daily in community logs | 5 mg + 2 mL BAC → 2,500 mcg/mL. 250 mcg = 10 units. |
| BPC-157 | 250–500 mcg | Daily in community logs | 5 mg + 2 mL BAC → 2,500 mcg/mL. 500 mcg = 20 units. |
| TB-500 | 2–5 mg per injection (folklore) | Often 2×/week, not a daily blend microdose | 5 mg + 1 mL BAC → 5 mg/mL. 2.5 mg = 50 units. |
Cycle folklore
On/off calendars below are community structures, usually blamed on GHK-Cu copper handling. They are not studied durations for this mix.
| Approach | On | Off | Note |
|---|---|---|---|
| Short community cycle | 4–6 weeks | 2–4 weeks | Same copper-off excuse as GLOW. Not a KPV PK holiday. |
| Extended community cycle | 8–12 weeks | About 4 weeks | More GHK-Cu mass per week than GLOW at the higher draw volumes. That is copper, not “anti-inflammatory loading.” |
| Anecdotal stretch | Up to 16 weeks | 4+ weeks | Forum duration. No safety file supports continuous four-peptide use. |
Storage and reconstitution steps
| State | Storage | Note |
|---|---|---|
| Lyophilized | Cold, dry, dark | Four peptides, one cake. Moisture is a discard for the whole lot. |
| Reconstituted | 2–8 °C. No freeze-thaw. | Treat reconstituted life as the shortest component window. 14–28 day vendor talk is not a stability study of this mix. |
| Appearance | Clear, possible faint blue-green | Copper tint can be GHK-Cu. Anything else: discard. |
- 01
Read the COA, not the nickname
Confirm each milligram on the label. GLOW and KLOW are vendor names. Ratios drift between lots.
- 02
Swab both stoppers
Alcohol on the blend vial and the bacteriostatic water. Let them dry.
- 03
Draw the water volume you actually chose
The tables on this page assume a common vendor water volume. If you add a different volume, rerun the blend calculator.
- 04
Aim at the glass wall
Inject water down the inside wall. Do not blast the cake. Foaming is wasted peptide, not a vibe.
- 05
Roll. Do not shake.
Gentle swirl until dissolved. GHK-Cu often tints the solution faint blue-green. That is copper, not contamination by itself. Cloudiness, clumps, or a brown shift is a discard.
- 06
Label date and fridge it
2–8 °C, dark. A multi-peptide cake is only as stable as the shortest-lived component. Vendor “30 days” claims are not a stability NDA.
- 07
Do the unit math before the first draw
Concentration = total mg ÷ water mL. Units on a U-100 syringe = mL × 100. Check it twice. Then check the COA again.
GLOW vs KLOW vs Wolverine
Ingredient count is not evidence quality. All three are vendor pairings. None has a combination RCT.
| Feature | Wolverine | GLOW | KLOW |
|---|---|---|---|
| In the bottle (typical vendor story) | BPC-157 + TB-500 7-mer | GHK-Cu + BPC-157 + TB-500 7-mer | GLOW four-way: adds KPV |
| Common advertised mass | Often 10–20 mg total | Often 70 mg (50/10/10) | Often 80 mg (50/10/10/10) |
| What the marketing is selling | Two-peptide recovery pair | Recovery pair plus copper-peptide skin story | GLOW plus an α-MSH fragment inflammation story |
| KPV | No | No | Yes (usually 10 mg) |
| GHK-Cu | No | Yes (usually the majority by mass) | Yes (usually the majority by mass) |
| Combination RCT | None | None | None |
| WADA | S0 via BPC-157 (and TB-500 as sold) | S0 via BPC-157 | S0 via BPC-157 |
| FDA compounding flag | Category 2 (BPC-157) | Category 2 (BPC-157) | Category 2 (BPC-157) |
- GLOW · Same three peptides without KPV. If you do not have a KPV-specific reason, this is the simpler cake.
- Wolverine · BPC-157 + TB-500 only. No copper peptide. No KPV.
- KPV · Read the mouse-colitis identity leaf. Do not upgrade it to a human gut protocol because it sat in KLOW.
- GHK-Cu · Majority mass. PIP and copper handling live here.
- BPC-157 · The WADA and Category 2 problem in this bottle.
- TB-500 · 7-mer, not Tβ4.
Supply math
Planning counts assume the advertised cake, the example water volume, and one syringe per day. Round up for priming. This is inventory arithmetic.
| If you run | Vials (advertised size) | Why |
|---|---|---|
| 4 weeks at 7.5 U/day | 1 × 80 mg | 7.5 U = 0.075 mL ≈ 2 mg. One 80 mg / 3 mL cake is ~40 draws. 28 days fits. |
| 4 weeks at 15 U/day | 2 × 80 mg | 15 U = 0.15 mL ≈ 4 mg. One cake is ~20 draws, not 28. You need a second vial for a 4-week daily calendar. |
| 4 weeks at 22.5 U/day | 3 × 80 mg | 22.5 U = 0.225 mL ≈ 6 mg. One cake is ~13 draws. Pages that print 30 injections at 22.5 units from 3 mL miscounted milliliters. |
Background & History
KLOW is GLOW with KPV poured into the same cake so a product page can say inflammation. The advertised 80 mg 50/10/10/10 split keeps GHK-Cu at 62.5% of every unit. Mouse colitis papers on KPV (Dalmasso 2008, Kannengiesser 2008) do not describe this bottle and are not Crohn’s or UC approvals. The four-way mix has not been studied as a mix.
Research Use Cases
- ✓Identity: GLOW components plus KPV, usually 50/10/10/10
- ✓Why every titration step scales copper peptide faster than KPV
- ✓When to buy a KPV vial instead of a four-peptide nickname
- ✓Not IBD, not mast cell, not autoimmune care
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Advertised 80 mg cake (example math) | 15 units = 0.15 mL ≈ 4.0 mg total from 3 mL | Once daily in community logs | At 50/10/10/10 that is ~2.5 mg GHK-Cu + ~500 mcg each of KPV, BPC-157, and TB-500. Other sites print 7.5 / 15 / 22.5 unit “titration.” That is arithmetic, not a trial arm. |
| Separate-vial folklore | Dose each leaf on its own page | Independent schedules | If you want KPV, buy KPV. Parking it inside a GHK-Cu-majority cake is not dose control. |
Administration
Timeline
Who it is for
GLOW plus KPV
LowThe only structural difference from GLOW is KPV. Difference is not superiority. Still a catalog pairing.
Gut / autoimmune marketing
LowThis site will not treat IBD, “leaky gut,” or autoimmunity from a KLOW page. KPV mouse papers stay on the KPV leaf.
Skin / wound marketing
LowGHK-Cu collagen papers exist. Blend copy is not a wound protocol.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 80 mg advertised cake (50/10/10/10) | 3 mL BAC | 26.7 mg/mL total | 15 U = 0.15 mL ≈ 4.0 mg total (~2.5 mg GHK-Cu + ~0.5 mg each other). COA wins. |
Change vial size or water volume? Open the blend calculator.
Safety & Considerations
GLOW components plus KPV. Contains BPC-157 (FDA Category 2, WADA S0). GHK-Cu is the usual injection-site pain and the copper-handling issue. Angiogenesis signaling: active malignancy is a hard no. Wilson’s and pregnancy: no. Four powders in one cake means four COA lines to verify. Not an autoimmune protocol.
Regulatory & Legal Status
Vendor blend typically GLOW components + KPV. Contains BPC-157 (FDA Category 2). The named blend is not an approved product. PCAC Jul 2026 review is advisory, not a final rule
Competitive athletes subject to anti-doping controls should not use KLOW Stack.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- No combination trial of the four peptides. Titration tables are milligram arithmetic, not a studied schedule.
- This site will not treat IBD or “leaky gut” from a KLOW page.
- Dalmasso 2008 and Kannengiesser 2008 stay on the KPV leaf. They do not describe this bottle.
Verdict
KLOW is a vendor name for GHK-Cu + BPC-157 + TB-500 + KPV. Common advertised SKU is 80 mg at 50/10/10/10. Not a gut-disease drug. KPV is not an IBD indication on this site.
Interactions & Contraindications
Same BPC-157 WADA S0 / Category 2 problem as GLOW, plus copper handling from GHK-Cu. No four-peptide PK. Not an IBD protocol.
Synergies & Common Stacks
Drop KPV and you are back at GLOW. If you cannot name a KPV-specific job, the fourth powder is marketing.
The only structural difference. Read the mouse-colitis leaf. Do not upgrade it because it sat in KLOW.
KLOW Stack vs. GLOW Stack
Canonical comparison: KLOW Stack vs GLOW Stack
| Attribute | KLOW Stack | GLOW Stack |
|---|---|---|
| Components | GHK-Cu + KPV + BPC-157 + TB-500 | GHK-Cu + BPC-157 + TB-500 |
| Common advertised mass | 80 mg at 50/10/10/10 | 70 mg at 50/10/10 |
| Why people pick it | KPV inflammation story | Fewer powders, same copper-peptide majority |
| KPV evidence in the mix | None. Mouse papers stay on the KPV leaf. | Not in the bottle |
| Combo trial | None | None |
Verdict: KLOW is not GLOW with a better evidence grade. It is GLOW plus an α-MSH fragment. Buy KPV separately if that is the actual job.
Frequently Asked Questions
What is the difference between GLOW and KLOW?▼
Does KPV make KLOW an IBD treatment?▼
What is the 80 mg 50/10/10/10 vial?▼
Why do other sites list 7.5, 15, and 22.5 unit steps?▼
Why does GHK-Cu dominate every draw?▼
Has the four-peptide mix been studied?▼
Why does the injection burn so much?▼
Is KLOW WADA-safe?▼
Should I pick KLOW over GLOW for inflammation?▼
How long does a reconstituted KLOW vial last?▼
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology (2008). PMID: 18061177
- Kannengiesser K, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflamm Bowel Dis (2008). PMID: 18092346
- Pickart L, Margolina A. “GHK peptide as a natural modulator of multiple cellular pathways in skin biology.” Biomed Res Int (2015). PMID: 26236730
- Sikiric P, et al. “Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing.” Curr Pharm Des (2018). PMID: 29936067
- Ho EN, et al. “Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by LC-MS.” Drug Test Anal (2012). PMID: 23084823
📚 Related Articles
Get KLOW Stack from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review